• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Glucotrack

Glucotrack first-in-human study of long-term CBGM implant meets endpoints

June 25, 2025 By Sean Whooley

Glucotrack 3-year continuous blood glucose monitor (CBGM)

Glucotrack (Nasdaq:GCTK) today announced the results from the first-in-human clinical study of its long-term continuous blood glucose monitor (CBGM). Rutherford, New Jersey-based Glucotrack shared findings at the American Diabetes Association’s 85th Scientific Sessions in Chicago. (See all the biggest stories out of ADA 2025 here.) Glucotrack’s device features no on-body external component. The company designed […]

Filed Under: Clinical Trials, Diabetes, Implants, Patient Monitoring, Technology Tagged With: ADA 2025, Glucotrack

The biggest diabetes tech stories out of ADA 2025

June 24, 2025 By Sean Whooley

ADA Logo in Chicago American Diabetes Association 85th Scientific Sessions

The biggest names in diabetes tech gathered in Chicago this past weekend for the American Diabetes Association’s 85th Scientific Sessions. At last year’s edition in Orlando, type 2 diabetes dominated the conversation. This time around, type 2 remained a hot topic, alongside new players in the continuous glucose monitor (CGM) and automated insulin delivery market, […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Technology Tagged With: abbott, ADA 2025, Beta Bionics, biolinq, Dexcom, Eli Lilly & Co., Glucotrack, Insulet, LifePlus, mannkind, Medtronic, minimed, modularmedical, PharmaSens, Senseonics, Sequel Med Tech, SiBionics, Tandem Diabetes Care, Vaxess Technologies

A new way to monitor glucose: Glucotrack explains 3-year CBGM implant technology

June 22, 2025 By Sean Whooley

Glucotrack 3-year continuous blood glucose monitor (CBGM)

Glucotrack (Nasdaq:GCTK) believes it can tap into a diabetes market that includes millions of people who aren’t being served completely. That’s according to the company’s Chief Scientific Officer, Mark Tapsak, who gave a presentation on the company’s long-term implantable continuous blood glucose monitor (CBGM) as part of the American Diabetes Association’s 85th Scientific Sessions’ “Innovation […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Featured, Implants, Patient Monitoring, Technology Tagged With: ADA 2025, Glucotrack

Glucotrack to effect a reverse stock split

June 13, 2025 By Sean Whooley

GlucoTrack updated Logo (1)

Glucotrack (Nasdaq:GCTK) announced that it plans to effect a 1-for-60 reverse stock split of its issued and outstanding common stock. Rutherford, New Jersey-based Glucotrack — maker of a long-term implantable continuous blood glucose monitor (CBGM) — intends for the split to go into effect when the market opens on Monday, June 16, 2025. Under the terms […]

Filed Under: Business/Financial News, Diabetes, Featured, Implants, Patient Monitoring, Technology, Wall Street Beat Tagged With: Glucotrack

Glucotrack can proceed with long-term glucose monitor study in Australia

May 13, 2025 By Sean Whooley

GlucoTrack updated Logo (1)

Glucotrack (Nasdaq:GCTK) announced today that it received a hospital’s ethical approval to study its continuous blood glucose monitor (CBGM). The St. Vincent’s Hospital Melbourne Human Research Ethics Committee (HREC) gave the nod for a long-term clinical study. It plans to include participants with both type 1 and type 2 diabetes using the CBGM. Rutherford, New […]

Filed Under: Business/Financial News, Clinical Trials, Diabetes, Drug-Device Combinations, Implants, Patient Monitoring, Technology Tagged With: Glucotrack

Glucotrack to bring implantable CBGM to automated insulin delivery system initiative in Europe

April 16, 2025 By Sean Whooley

GlucoTrack updated Logo (1)

Glucotrack (Nasdaq:GCTK) announced today that it intends to participate in a bionic pancreas initiative in Europe. FORGETDIABETES aims to develop a long-term automated insulin delivery system. This system should enable optimal glucose control without patient intervention. The initiative, funded by the European Union’s Horizon 2020 research and innovation program, offers support from basic research to […]

Filed Under: Business/Financial News, Diabetes, Drug-Device Combinations, Featured, Patient Monitoring, Research & Development Tagged With: Glucotrack

Glucotrack expects FDA IDE for implantable CBGM this year

April 1, 2025 By Sean Whooley

GlucoTrack updated Logo (1)

Glucotrack (Nasdaq:GCTK) announced that it expects FDA investigational device exemption (IDE) for its long-term CBGM later this year. Rutherford, New Jersey-based Glucotrack develops a long-term implantable continuous blood glucose monitor (CBGM). The device features no on-body external component. The company designed it for three years of continuous, accurate blood glucose monitoring for a more convenient, […]

Filed Under: Business/Financial News, Diabetes, Featured, Implants, Patient Monitoring, Technology Tagged With: Glucotrack

Glucotrack completes first-in-human continuous blood glucose monitor implant study

February 4, 2025 By Sean Whooley

GlucoTrack updated Logo (1)

Glucotrack (Nasdaq:GCTK) announced today that it completed the first-in-human clinical study of its continuous blood glucose monitor (CBGM). The study included participants with both type 1 and type 2 diabetes and began enrolling patients in early December 2024. Unlike traditional CGMs that measure glucose in interstitial fluid, the CBGM measures glucose levels directly from the […]

Filed Under: Clinical Trials, Diabetes, Featured, Implants, Patient Monitoring, Technology Tagged With: Glucotrack

Glucotrack begins enrollment for first human trial of continuous blood glucose monitor

December 3, 2024 By Sean Whooley

GlucoTrack updated Logo (1)

Glucotrack (Nasdaq:GCTK) announced today that it commenced patient enrollment for its short-term human clinical study. The study focuses on the company’s continuous blood glucose monitor (CBGM) and includes participants with both type 1 and type 2 diabetes. Rutherford, New Jersey-based Glucotrack expects data from the study in 6-8 weeks. Unlike traditional CGMs that measure glucose […]

Filed Under: Clinical Trials, Diabetes, Featured, Implants, Patient Monitoring, Technology Tagged With: Glucotrack

Glucotrack survey highlights interest in 3-year continuous blood glucose monitor implant

August 15, 2024 By Sean Whooley

GlucoTrack

Glucotrack (Nasdaq:GCTK) today announced findings from a market research study demonstrating the acceptance of its CBGM concept. Rutherford, New Jersey-based Glucotrack develops a small device placed under the skin for continuous blood glucose monitoring. It designed the technology to deliver continuous, accurate blood glucose monitoring for up to three years. This would eliminate some of […]

Filed Under: Diabetes, Implants, Patient Monitoring, Technology Tagged With: Glucotrack

  • Page 1
  • Page 2
  • Page 3
  • Go to Next Page »

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS